Procept BioRobotics Corporation (PRCT)

Market Closed

16 Oct, 08:00 PM

NASDAQ (NMS)

17. 57

-0.58

-3.1956%

1.05B Market Cap

- P/E Ratio

- Div Yield

1.2M Volume

-2 Eps

$ 18.15

Previous Close

Investors:

CSP

+47

Add Transaction

Day Range

17.52 18.67

Year Range

16.66 38.11

Want to track PRCT and more in your Portfolio? 🎯

Get Started For Free

PROCEPT BioRobotics Corporation (PRCT) Q2 2026 Earnings Call Transcript

Seekingalpha | 2 months ago

PROCEPT BioRobotics Q2 Earnings Call Highlights

PROCEPT BioRobotics NASDAQ: PRCT reported second-quarter revenue growth of 19% year over year while lowering its full-year U.S. procedure outlook, citing softer activity at legacy AquaBeam accounts. Management said newer HYDROS Robotic System accounts continued to show stronger utilization, supporting an accelerated replacement strategy for older systems.

Marketbeat | 2 months ago

PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Beats Revenue Estimates

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.35 per share a year ago.

Zacks | 2 months ago

PROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seekingalpha | 5 months ago

PROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call Transcript

Seekingalpha | 5 months ago

PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.45 per share a year ago.

Zacks | 5 months ago

Procept BioRobotics: An Undervalued Surgical Robotics Growth Story

PROCEPT BioRobotics is rated buy, offering a unique, FDA-cleared Aquablation platform for BPH, targeting a large, underpenetrated market. PRCT trades at 2.9x forward EV/2026E revenue, a deep discount to peers, despite 27-33% guided revenue growth and improving margins. A recent Q4 revenue miss and rebate changes triggered a 63% stock drop, but fundamentals remain strong with $286M cash and minimal dilution risk.

Seekingalpha | 6 months ago